Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Current Assets (2019 - 2026)

Biodesix filings provide 8 years of Current Assets readings, the most recent being $40.9 million for Q1 2026.

  • On a quarterly basis, Current Assets rose 38.11% to $40.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $40.9 million, a 38.11% increase, with the full-year FY2025 number at $32.5 million, down 17.64% from a year prior.
  • Current Assets hit $40.9 million in Q1 2026 for Biodesix, up from $32.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $57.6 million in Q2 2024 to a low of $24.1 million in Q3 2022.
  • Median Current Assets over the past 5 years was $33.4 million (2025), compared with a mean of $35.7 million.
  • Biggest five-year swings in Current Assets: crashed 66.48% in 2022 and later surged 128.08% in 2024.
  • Biodesix's Current Assets stood at $53.3 million in 2022, then dropped by 25.6% to $39.7 million in 2023, then decreased by 0.5% to $39.5 million in 2024, then dropped by 17.64% to $32.5 million in 2025, then increased by 25.81% to $40.9 million in 2026.
  • The last three reported values for Current Assets were $40.9 million (Q1 2026), $32.5 million (Q4 2025), and $33.4 million (Q3 2025) per Business Quant data.